Compare TNC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNC | NVCR |
|---|---|---|
| Founded | 1870 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | TNC | NVCR |
|---|---|---|
| Price | $73.81 | $13.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $102.00 | $28.42 |
| AVG Volume (30 Days) | 140.0K | ★ 1.5M |
| Earning Date | 02-17-2026 | 10-30-2025 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $1,240,800,000.00 | $642,269,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | $5.63 | $5.62 |
| P/E Ratio | $25.42 | ★ N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $67.32 | $10.70 |
| 52 Week High | $90.44 | $31.17 |
| Indicator | TNC | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 54.16 |
| Support Level | $73.07 | $12.88 |
| Resistance Level | $75.87 | $13.64 |
| Average True Range (ATR) | 1.39 | 0.47 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 14.29 | 49.70 |
Tennant Co is a manufacturer of floor cleaning equipment, wood flooring, and wood products. It operates in four geographic business units including North America; Latin America; Europe, Middle East, Africa; and Asia Pacific. The company offers products and solutions consisting of mechanized cleaning equipment, detergent-free, and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, specialty surface coatings, and business solutions such as financing, rental and leasing programs, and machine-to-machine asset management solutions.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.